Abstract

Mozambique introduced monovalent rotavirus vaccine (Rotarix®) in September 2015. We evaluated the effectiveness of Rotarix® under conditions of routine use in Mozambican children hospitalized with acute gastroenteritis (AGE). A test negative case-control analysis was performed on data collected during 2017–2019 from children <5 years old, admitted with AGE in seven sentinel hospital sites in Mozambique. Adjusted VE was calculated for ≥1 dose of vaccine vs. zero doses using unconditional logistic regression, where VE = (1 − aOR) × 100%. VE estimates were stratified by age group, AGE severity, malnutrition, and genotype. Among 689 children eligible for analysis, 23.7% were rotavirus positive (cases) and 76.3% were negative (controls). The adjusted VE of ≥1 dose in children aged 6–11 months was 52.0% (95% CI, −11, 79), and −24.0% (95% CI, −459, 62) among children aged 12–23 months. Estimated VE was lower in stunted than non-stunted children (14% (95% CI, −138, 66) vs. 59% (95% CI, −125, 91)). Rotavirus vaccination appeared moderately effective against rotavirus gastroenteritis hospitalization in young Mozambican children. VE point estimates were lower in older and stunted children, although confidence intervals were wide and overlapped across strata. These findings provide additional evidence for other high-mortality countries considering rotavirus vaccine introduction.

Highlights

  • Rotavirus is the most important cause of moderate to severe gastroenteritis in children under five years old [1]

  • The Centro de Investigação em Saúde de Manhiça (CISM) Diarrhoeal Disease Surveillance platform was approved by the same Committee under the reference number 209/CNBS/15; IRB00002657

  • The present analysis describes the “real-world” vaccine effectiveness (VE) of monovalent rotavirus vaccine in Mozambican children hospitalized with acute gastroenteritis (AGE) during 2017–2019

Read more

Summary

Introduction

Rotavirus is the most important cause of moderate to severe gastroenteritis in children under five years old [1]. In 2019, about 128,500 deaths by rotavirus were reported worldwide, of which 81.5% (104,733) occurred in sub-Saharan Africa [1]. In Mozambique, the average annual number of deaths due to rotavirus gastroenteritis (RVGE) among children under five from 2017 to 2019 was 1126, and the mortality rate varied from 27 to 19 per 100,000 children [2]. The burden of malnutrition is high in sub-Saharan African countries [7] and in Mozambique, where more than 40% of children less than five years old suffer from chronic malnutrition [8]. Assessing rotavirus vaccine performance in countries with a high burden of malnutrition is important given that this condition may reduce protection in children [6]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.